Smallpox is a serious and sometimes fatal contagious disease. It is caused by either of two virus variants, Variola major and Variola minor. The signs and symptoms usually appear 12–14 days after infection and then the rash and sores usually scab over and fall off within 4 weeks. However, in rare cases it can cause serious complications or even death. Smallpox treatment options include vaccinia immune globulin, ST-246, and Cidofovir. The global smallpox treatment market aims to develop effective therapeutics and vaccines for the treatment and prevention of smallpox infections.

The global Smallpox Treatment Market is estimated to be valued at US$ 68.7 Mn in 2023 and is expected to exhibit a CAGR of 1.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Growing prevalence of viral infections worldwide has emerged as a major driver for the global smallpox treatment market. As per WHO, around 10 million people were infected with smallpox globally each year in the 1950s. Although smallpox has been eradicated as a result of an unprecedented global vaccination program, concerns of bioterrorism using variola virus have amplified the need for effective therapeutics. Around 40 countries were reported to have smallpox material in 1983 and this heightened fears of weaponization of the virus. Thus, the threat of deliberate release of variola virus stimulates continued research for smallpox therapeutics and vaccines. Development of novel vaccines and therapeutics addressing safety, immunogenicity and cost-effectiveness offer lucrative growth opportunities for players in the global smallpox treatment market during the forecast period.

Porter's Analysis

Threat of new entrants: The smallpox treatment market has high barriers of entry due to strict regulations imposed by regulatory bodies and high R&D costs associated with drug development.

Bargaining power of buyers: The bargaining power of buyers is moderate as smallpox treatment has limited availability from a few major manufacturers.

Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitute raw materials and differentiation in products.

Threat of new substitutes: New substitute treatments are in pipeline which can increase competition in long run.

Competitive rivalry: Intense due to presence of major competitors.

SWOT Analysis

Strength: Established distribution network and manufacturing infrastructure of major players. Research collaboration results in innovation.

Weakness: High R&D and manufacturing costs. Limited target population reduces revenue potential.

Opportunity: Government support for preparedness against bioterrorism threats increase funding. Emerging markets yet to be tapped.

Threats: stringent regulations. Threat of substitute emerging therapies.

Key Takeaways

The global Smallpox Treatment Market Growth is expected to witness high growth supported by government initiatives for biodefense preparedness. The North American region currently dominates the market owing to presence of major players and increasing government funding.

Regional analysis indicates fastest growth is anticipated in the Asia Pacific region over the forecast period. Increasing awareness, improving healthcare infrastructure and growing investment by market players are factors driving market growth in the region.

Key players operating in the smallpox treatment market are SIGA Technologies Inc., Bavarian Nordic A/S, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Emergent BioSolutions Inc., Novartis International AG, GlaxoSmithKline plc, Sanofi Pasteur SA, Merck & Co. Inc., Pfizer Inc., Bharat Biotech International Ltd., BioCryst Pharmaceuticals Inc., Chimerix Inc. and Nanotherapeutics Inc. Key players are focused on new drug developments and strategic collaborations for sustained growth in the future.

For more insights, read- https://cmiinfopiece.blogspot.com/2023/12/the-global-smallpox-treatment-market.html